|  |  |  |
| --- | --- | --- |
|  | **TAZ expression in the nucleus** |  |
|  |  | **0** | **1** | **2** | **3** | **R (Pearson)** | **p-value** |
| **Histology** |
|  | ***Total (%)*** | ***22 (20.6)*** | ***60 (56.1)*** | ***19 (17.7)*** | ***6 (5.6)*** | **0.5999 <0.0001** |
|  | **SCC** | **0** | **16** | **17** | **5** |
|  | **ADC** | **10** | **24** | **2** | **1** |
|  | **SCLC** | **12** | **20** | **0** | **0** |
| **Age at diagnosis (years)** |
| **< 65** | ***total*** | ***13 (12.1)*** | ***26 (24.3)*** | ***5 (4.7)*** | ***3 (2.8)*** | **-0.0718 0.467397** |
|  | **SCC** | **0** | **8** | **5** | **3** |
|  | **ADC** | **5** | **9** | **0** | **0** |
|  | **SCLC** | **8** | **9** | **0** | **0** |
| **≥ 65** | ***total*** | ***9 (8.4)*** | ***34 (31.8)*** | ***14 (13.1)*** | ***3 (2.8)*** |
|  | **SCC** | **0** | **8** | **12** | **2** |
|  | **ADC** | **5** | **15** | **2** | **1** |
|  | **SCLC** | **4** | **11** | **0** | **0** |
| **Gender** |
| **male** | ***total*** | ***13 (12.1)*** | ***40 (37.4)*** | ***16 (15.0)*** | ***4 (3.7)*** | **0.1075 0.270407** |
|  | **SCC** | **0** | **11** | **14** | **4** |
|  | **ADC** | **7** | **18** | **2** | **0** |
|  | **SCLC** | **6** | **11** | **0** | **0** |
| **female** | ***total*** | ***9 (8.4)*** | ***20 (18.7)*** | ***3 (2.8)*** | ***2 (1.9)*** |
|  | **SCC** | **0** | **6** | **2** | **1** |
|  | **ADC** | **3** | **5** | **1** | **1** |
|  | **SCLC** | **6** | **9** | **0** | **0** |

**Table 1. Clinicopathological characteristics.** SCC histological subtype, age at diagnosis < 65 years at diagnosis and male gender are correlated to the TAZ expression in the nucleus. Biopsy material was combined on tissue micro arrays comprising SCC (n=38), ADC (n=37) and SCLC (n=32). Statistical analysis was performed using Pearson Correlation.